Skip to main content

Table 1 Utility and cost values, base case analysis

From: Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81–8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting

Utilities

State

Mean (SD)

Source

Pettersson score 0–4

0.82 (± 0.13)

Fischer, K. et al.[6]

Pettersson score 5–12

0.81 (± 0.12)

Pettersson score 13–21

0.77 (± 0.13)

Pettersson score 22–39

0.74 (± 0.12)

Pettersson score 40–78

0.72 (± 0.11)

Orthopaedic surgery

-0.39 (± 0.04)

Ballal, R. D. et al.[19] Utility decrement is assumed to last for 30.4 days. Standard deviation not reported, 10% assumed

Hospitalisation due to major bleed

-0.39 (± 0.04)

Assumption. Utility decrement is assumed to be the same as for orthopaedic surgery but for a shorter time period (3.6 days)

Costs

Input

Mean (CNY)

Source

BAY 81–8973 per IU

4.488

Huo et al.[20]

rAHF-PFMper IU

4.488

Huo et al.[20]

Hospitalization for major bleed

74,122

Expert opinion, based on survey

Physician visit

500

Expert opinion, based on survey

Cost of orthopaedic surgery

300,465

Expert opinion, based on survey

Rehabilitation costs

937.50

Expert opinion, based on survey

Total compensation per hour

25.40

National Bureau of Statistics of China[21]

Resource Use

Input

Unit/Frequency

Source

Extra dose for treatment of bleed – BAY 81–8973

24.11 IU/kg

Calculated

Extra dose for treatment of bleed – rAHF-PFM

24.55 IU/kg

Calculated

Doctor visits (with or without joint bleeds)

12 / year

Expert opinion

Retirement age

60

China labour statistics[22]

Full time employment

45.6%

Sun et al.[23]

Missing days of work, annual

3.40

Chen et al. 2017[24]

  1. rAHF-PFM: antihemophilic factor (recombinant) plasma/albumin-free method